Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3351541 | 1.00 | ACACB (0.47) | ACACBKDM6BKMOALDH1A1POLB | |
| SCHEMBL4501882 | 0.86 | ACACB (0.47) | ACACBALDH1A1POLBHPGDSMN1; SMN2 | |
| SCHEMBL3352484 | 0.78 | ACACB (0.43) | ACACBKMOALDH1A1POLBHPGD | |
| SCHEMBL4501888 | 0.75 | ACACB (0.41) | ACACBKMOALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4501885 | 0.74 | ACACB (0.42) | ACACBKMOALDH1A1HPGDKMT2A | |
| SCHEMBL3353814 | 0.72 | KDM6B (0.37) | KDM6BALDH1A1KDM4E | |
| SCHEMBL3353809 | 0.72 | KDM6B (0.37) | KDM6BALDH1A1KDM4E | |
| SCHEMBL16435008 | 0.71 | ACACB (0.43) | ACACBALDH1A1POLBHPGDTP53 | |
| SCHEMBL10024350 | 0.70 | KDM6B (0.53) | KDM6BPOLBMAPTKMT2AKDM4E | |
| SCHEMBL13907747 | 0.69 | KMO (0.42) | ACACBKMOALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696209-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| CN-101146799-A | Cgrp-antagonists, process for their preparation as well as their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1863799-A1 | CGRP-ANTAGONISTS, PROCESS FOR THEIR PREPARATION AS WELL AS THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1770091-A1 | CGRP-antagonists, process for their preparation as well as their use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006100009-A1 | CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACACB 4874/4885KDM6B 4799/4885KMO 2610/4885 |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACACB 4862/4885KDM6B 4822/4885KMO 3018/4885 |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACACB 4862/4885KDM6B 4822/4885KMO 3018/4885 |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACACB 4836/4885KDM6B 4699/4885KMO 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.